

1653 #3

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)  
Approved for use through 10/31/02. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	<b>Application Number</b>	09/752,533	
	<b>Filing Date</b>	December 29, 2000	
	<b>First Named Inventor</b>	Stephen M. COUTTS	
	<b>Group Art Unit</b>	1653	
	<b>Examiner Name</b>	To Be Assigned	
<b>Total Number Of Pages In This Submission</b>	8	<b>Attorney Docket No.</b>	252312005704

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO-1449 - 4 pages 2. Return Receipt Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement - 3 pages	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<b>RECEIVED</b> AUG 21 2001 TECH CENTER 1600/2900	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<b>Remarks</b>	

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT	
<b>Firm or Individual Name</b>	Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018
<b>Signature</b>	
<b>Date</b>	August 8, 2001

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on August 8, 2001.
 Aurelia Caparas

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT  
Docket No. 252312005704

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on August 8, 2001.

  
Aurelia Caparas

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Stephen M. COUTTS et al.

Serial No.: 09/752,533

Filing Date: December 29, 2000

For: CONJUGATES OF CHEMICALLY  
DEFINED NON-POLYMERIC  
VALENCY PLATFORM MOLECULES  
AND BIOLOGICALLY ACTIVE  
MOLECULES

Examiner: To Be Assigned

Group Art Unit: 1653

**RECEIVED**  
AUG 21 2001  
TECH CENTER 1000/2000

**INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. The documents are on record in the related application Serial Number 08/769,041, filed December 18, 1996. Copies of the documents were submitted in an Information Disclosure Statement and/or Office Action directed to related application Serial Number 08/769,041, filed December 18, 1996 and/or application Serial Number 08/453,254 filed May 30, 1997 and/or application Serial Number 08/152,506 and/or application Serial Number 07/914,869 filed July 15, 1992 and/or application Serial Number 08/118,055 filed September 8, 1993 and, accordingly, copies

pa-604625

are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). Copies of the documents can be provided upon request by The Examiner. The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \* is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.

Applicants would appreciate the Examiner's initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by

third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 252312005704. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: August 8, 2001

Respectfully submitted,


By:   
\_\_\_\_\_  
Madeline I. Johnston, Ph.D.  
Registration No. 36,174

Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
Telephone: (650) 813-5840  
Facsimile: (650) 494-0792

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)



Docket Number 252312005704

Application Number 09/752,533

Applicant

Stephen M. COUTTS et al.

Filing Date December 29, 2000

Group Art Unit 1653

Mailing Date August 8, 2001

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	12/21/1965	3,225,063	D'Alelio et al.			
	2.	03/04/1980	4,191,668	Katz			
	3.	09/02/1980	4,220,565	Katz			
	4.	04/26/1983	4,381,239	Chibata et al.			
	5.	06/14/1983	4,388,441	Katz			
	6.	03/17/1987	4,650,675	Borel et al.			
	7.	03/15/1988	4,731,373	Barner et al			
	8.	06/14/1988	4,751,181	Keene			
	9.	02/28/1989	4,808,705	Ferris			
	10.	06/12/1990	4,933,288	Greenfield			
	11.	01/01/1991	4,981,979	Sivam			
	12.	06/30/1992	5,126,131	Dintzis et al.			
	13.	07/14/1992	5,130,116	Woo et al.			
	14.	11/10/1992	5,162,515	Conrad et al.			
	15.	12/07/1993	5,268,454	Barstad et al.			
	16.	01/04/1994	5,276,013	Conrad et al.			
	17.	12/06/1994	5,370,871	Dintzis et al.			
	18.	02/21/1995	5,391,785	Jones et al.			
	19.	09/03/1996	5,552,391	Coutts et al.			
	20.	02/25/1997	5,606,047	Coutts et al.			
	21.	05/27/1997	5,633,395	Coutts et al.			
	22.	12/23/1997	5,700,919	Seliger et al.			
	23.	03/10/1998	5,726,329	Jones et al.			
	24.	07/28/1998	5,786,512	Jones et al.			
	25.	02/23/1999	5,874,409	Victoria et al.			
	26.	02/23/1999	5,874,552	Jones et al.			
	27.	02/08/2000	6,022,544	Dintzis et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 252312005704

Application Number 09/752,533

Applicant


Stephen M. COUTTS et al.

Filing Date December 29, 2000

Group Art Unit 1635

Mailing Date August 6, 2001

AUG 16 2001



28.	05/09/2000	6,060,056	Coutts et al.
29.	03/27/2001	6,207,160	Victoria et al.

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
	30.	09/30/1991	CA 2,079,109	Canada				
	31.	05/08/1991	DE 3,937,116	Germany			Abstract	
	32.	07/10/1985	EP 0 147 768	Europe			Abstract	
	33.	02/14/1990	EP 0 354 323	Europe				
	34.	11/28/1990	EP 0 399 330	Europe			Abstract	
	35.	07/24/1991	EP 0 438 259	Europe				
	36.	08/21/1991	EP 0 442 724	Europe				
	37.	03/15/1995	EP 0 642 798	Europe				
	38.	01/11/1991	JP 3-5495	Japan			Abstract	
	39.	02/17/1986	JP 61-033195	Japan			Partial	
	40.	08/29/1985	WO 85/03704	PCT				
	41.	07/17/1986	WO 86/04093	PCT				
	42.	06/07/1987	WO 87/02777	PCT				
	43.	01/15/1987	WO 87/00056	PCT				
	44.	12/15/1988	WO 88/09810	PCT				
	45.	10/19/1989	WO 89/09628	PCT				
	46.	12/14/1989	WO 89/12060	PCT				
	47.	02/20/1992	WO 92/02531	PCT				
	48.	07/09/1992	WO 92/11029	PCT				
	49.	06/24/1993	WO 93/12145	PCT				
	50.	03/16/1995	WO 95/07073	PCT				
	51.	12/19/1996	WO 96/40197	PCT				
	52.	12/11/1997	WO 97/46251	PCT				

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 252312005704

Application Number 09/752,533

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)


Applicant

Stephen M. COUTTS et al.

Filing Date December 29, 2000

Group Art Unit 1653

Mailing Date August 2, 2001



Examiner Initials	Ref. No.	Title
	53.	Agrawal et al., (1986) "Efficient Methods for Attaching Non-Radio-Active Labels to the 5' End of Synthetic Oligonucleotides," <i>Nucl. Acids Res.</i> 14:6227-6245.
	54.	Asseline, U. et al. (1990). "New Solid-Phase for Automated Synthesis of Oligonucleotides Containing an Amino-Alkylo Linker at Their 3'-End," <i>Tetrahedron Letts.</i> 31(1):81-84.
	55.	Borel et al. (1973). "Prevention of Murine Lupus Nephritis by Carris-Dependent Induction of Immunologic Tolerance to Denatured DNA," <i>Science</i> 182:76-78.
	56.	Borel et al. (1986). "A Possible New Therapy of Systemic Lupus Erythematosus (SLE)," <i>Ann. N.Y. Acad. Sci.</i> 475:296-306.
	57.	Borel et al. (1988). "Oligonucleotide Linked to Human Gammaglobulin Specifically Diminishes Anti-DNA Antibody Formation in Cultured Lymphoid Cells from Patients with Systemic Lupus Erythematosus," <i>J. Clin. Invest.</i> 82:1901-1907.
	58.	Borel et al. (1990). "A Novel Technique to Link Either Proteins or Peptides to Gammaglobulin to Construct Tolerogens," <i>J. Immunol. Methods</i> 126:159-168.
	59.	Conrad, M.J. et al. "Conjugates of Stable Polymer and Polynucleotide - Tolerogens for Human Systemic Lupus Erythematosus," Derwents Database record for European Patent No. EP 0 438 259, July 1991.
	60.	Dintzis, R.Z. et al. (July 1985). Inhibition of Anti-DNP Antibody Formation by High Doses of DNP-Polyacrylamide Molecules; Effects of Hapten Density and Hapten Valence," <i>J. Immunol.</i> 135(1):423-427.
	61.	Dreef, C.E. et al. (1988). "Synthesis of 1-O-(1, 2-DI-O-Palmitoyl-SN-Glycero-3-Phospho)-D-MYO-Inositol 4, 5-Biphosphate: An Analogue of Naturally Occurring (Ptd)Ins(4,5)P <sub>2</sub> ," <i>Tetrahedron Letts.</i> 29(49):6513-6516.
	62.	Efimov, V.A. et al. (1993). "Synthesis of Polyethylene Glycol-Oligonucleotide Conjugates," <i>Bioorg. Khim.</i> , 19(8):800-804 (English abstract on page 804).
	63.	Eshhar et al. (1975). "Induction of Tolerance to Nucleic Acid Determinants by Administration of a Complex of Nucleoside D-Glutamic Acid and D-Lysine (D-GL)," <i>J. Immunol.</i> 144:872-876.
	64.	Frenkel et al. (1987). "Inhibition of RNA and DNA Polymerases by the Product of the Reaction of Selenite with Sulfhydryl Compounds," <i>Mol. Pharm.</i> 31(1):112-116.
	65.	Gupta, K.C. et al. (October 28, 1991). "A General Method for the Synthesis of 3'-Sulfhydryl and Phosphate Group Containing Oligonucleotides," <i>Chem. Abstracts</i> 115(17):976. (Abstract Only).
	66.	Hertler, A.A. (1988). "Human Immune Response to Immunotoxins," <i>Cancer Treatment Research</i> 37:475-480.
	67.	Jones, D.S. et al. (1994). "Conjugates of Double-Stranded Oligonucleotides with Poly(ethylene glycol) and Keyhole Limpet Hemocyanin: A Model for Treating Systemic Lupus Erythematosus," <i>Bioconjugate Chem.</i> 5:390-399.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 252312005704

Application Number 09/752,533

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

Applicant

Stephen M. COUTTS et al.

Filing Date December 29, 2000

Group Art Unit 1653

Mailing Date August 8, 2001

(Use several sheets if necessary)

68

Jones, D.S. et al. (1995). "Immunospecific Reduction of Antioligonucleotide Antibody-Forming Cells with a Tetrakis-oligonucleotide Conjugate (LJP 394), a Therapeutic Candidate for the Treatment of Lupus Nephritis," *J. Med. Chem.* 38:2138-2144.

69.

Kremsky et al. (1987). "Immobilization of DNA via Oligonucleotides Containing an Aldehyde or Carboxylic Acid Group at the 5' Terminus," *Nucl. Acids. Res.* 15:2891-2909.

70.

Mitsuo, N. (1978). "Permeability of Liposomal Membranes Composed of Unnatural Types of Synthetic Lecithin-Analogues," *Chem. Pharm. Bull.* 26(5):1493

71.

Nossal, G.J.V. (14 July 1989). "Immunologic Tolerance: Collaboration Between Antigen and Lymphokies," *Science* 245(4914):147-,153.

72.

Papalian, M. et al. (1980). "Reaction of Systemic Lupus Erythematosus Antinative DNA Antibodies with Native DNA Fragments from 20 to 1,200 Base Pairs," *J. Clin. Invest.* 65:469-477.

73.

Parker et al. (1974). "Modification of NZB/NZW F<sub>1</sub> Autoimmune Disease by Development of Tolerance to DNA," *J. Immunol.* 113:292-297.

74.

Sasaki et al. (1982). "Induction of Immunological Tolerance to Single-Stranded and Double-Stranded DNA," *Scand. J. Immunol.* 16:191-200.

75.

Sehon, A.H. (1991). "Suppression of Antibody Responses by Conjugates of Antigens and Monomethypoly(Ethylene Glycol)," *Advanced Drug Delivery Reviews* 6:203-217.

76.

Sehon. (1982). "Suppression of IgE Antibody Responses with Tolerogenic Conjugates of Allergens and Haptens," *Prog. Allergy* 32:161-202.

77.

Stollar et al. (1980). "Secondary Structure in Denatured DNA is Responsible for its Reaction with Antinative DNA Antibodies of Systematic Lupus Erythematosus Sera," *J. Clin. Invest.* 66:210-219.

78.

Usman, N. et al. (1988). "Preparation of Glyceronucleoside Phosphoramidite Synthons and Their Use in the Solid Phase Synthesis of Acyclic Oligonucleotides," *Tetrahedron Letts.* 29(38):4831-4834.

79.

Verkade, P.E. et al. (1940). "Synthesen von Glyceriden mit Hilfe von Tritylverbindungen IV," *Recl. Trav. Pays-Bas*, (no English Abstract).

80.

Wilkinson et al. (1987). "Tolerance Induction in Mice by Conjugates of Monoclonal Immunoglobulins and Monomethoxypolyethylene Glycol," *J. Immunol.* 139:326-331.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED  
AUG 2 2001  
TECH CENT L 1600/2900